
President and COO, G & W Laboratories Inc
Member of the Healthcare Council
Kurt Orlofski, CPA, CMA, is President and COO at G & W Laboratories. Mr. Orlofski was previously, President of Wockhardt USA. Wockhardt is a global leader in pharmaceuticals and biotechnology. Previously, Mr. Orlofski was President and Chief Executive Officer of Pliva, the US subsidiary of the global specialty pharmaceutical company Pliva. He was responsible for all Pliva US businesses including USD300m of generics business. Previously, Mr. Orlofski was Senior Vice President of Global Business Development at Alpharma Human Pharmaceuticals. His areas of expertise include pharmaceutical general management, operations and quality management, sales and marketing in generics, new business unit start-ups, product acquisition, brand and generic in and out licensing of products and technology, business unit and asset sales and acquisitions including integration, contract manufacturing deals in and out, and negotiation and execution of supplier and customer supply agreements. (This is me - Update Profile)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Lupin acquisition in Japan a positive
October 16, 2007
Indian Drug Maker Lupin to Acquire Kyowa Pharmaceutical | www.pipelinereview.com
Japan is the second largest generic market in the world. Kyowa Pharmaceuticals has a real presence in the Japanese pharmaceutical market. Allows Kyowa to leverage low cost Indian manufacturing while Lupin gains a large and growing market for distribution.
| Study Group Name | No. Members |
|---|---|
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| Generic Drug Economic Experts | 766 |
| Former C-Level Executives in the Healthcare Council in Member Programs | 289 |
| Medical Geneticists (US) | 85 |
Kurt Orlofski has not participated in any GLG Live Meetings.